CVS Group (AIM:CVSG) reported adjusted EBITDA of approximately £134 million for the year ended 30 June 2025, in line with market consensus, according to a trading update released on Thursday.
The veterinary services provider said revenue from continuing operations rose 5.4% to £673.2 million, with like-for-like sales up 0.2%.
Growth was supported by continued expansion in Australia, where seven acquisitions added 15 practice sites for £29.2 million. A further two-site deal closed after the year-end, bringing the Australian footprint to 45 sites.
UK acquisition activity meanwhile remained on hold pending the outcome of a Competition and Markets Authority’s investigation, the outcome for which was delayed until September.
“As previously announced, full year revenue growth and like-for-like sales were impacted by softer market conditions in the UK,” the company stated.